National Philanthropic Trust’s Fate Therapeutics FATE Stock Holding History

National Philanthropic Trust’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$338K	Hold	125,000	–	–	﹤0.01%	336
2026 Q1	$150K	Hold	125,000	–	–	﹤0.01%	353
2025 Q4	$123K	Hold	125,000	–	–	﹤0.01%	379
2025 Q3	$158K	Hold	125,000	–	–	﹤0.01%	313
2025 Q2	$140K	Hold	125,000	–	–	﹤0.01%	281
2025 Q1	$98.8K	Hold	125,000	–	–	﹤0.01%	262
2024 Q4	$206K	Hold	125,000	–	–	﹤0.01%	258
2024 Q3	$438K	Hold	125,000	–	–	0.01%	204
2024 Q2	$410K	Hold	125,000	–	–	0.01%	211
2024 Q1	$918K	Hold	125,000	–	–	0.02%	164
2023 Q4	$468K	Buy	+125,000	New	+$295K	0.01%	212

Other funds holding FATE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

National Philanthropic Trust's FATE Position: Q2 2026 in Review

National Philanthropic Trust held its Fate Therapeutics (FATE) position steady in Q2 2026 at 125,000 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #336.

National Philanthropic Trust first reported a position in FATE in Q4 2023 and has held it in 11 quarters since. The position peaked at $918K in Q1 2024. 141 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

National Philanthropic Trust held 125,000 shares of Fate Therapeutics worth $338K as of Q2 2026.
National Philanthropic Trust left its Fate Therapeutics share count unchanged in Q2 2026.
Fate Therapeutics made up ﹤0.01% of National Philanthropic Trust's portfolio in Q2 2026, its #336 holding.
National Philanthropic Trust first reported a position in Fate Therapeutics in Q4 2023 and has held it in 11 quarters since.
National Philanthropic Trust's Fate Therapeutics position peaked at $918K in Q1 2024.
141 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on National Philanthropic Trust's 13F filing for Q2 2026, filed 14 Aug 2026.